Original Article
Efficacy analysis of fecal microbiota transplantation in the treatment of 406 cases with gastrointestinal disorders
Li Ning, Tian Hongliang, Ma Chunlian, Ding Chao, Ge Xiaolong, Gu Lili, Zhang Xuelei, Yang Bo, Hua Yue, Zhu Yifan, Zhou Yan
Published 2017-01-25
Cite as Chin J Gastrointest Surg, 2017, 20(1): 40-46. DOI: 10.3760/cma.j.issn.1671-0274.2017.01.009
Abstract
ObjectiveTo evaluate the efficacy and safety of fecal microbiota transplantation (FMT) for gastrointestinal disorders.
MethodsRetrospective analysis of the clinical data of 406 patients who underwent FMT from May 2014 to April 2016 in the Intestinal Microenvironment Treatment Centre of Nanjing General Hospital was performed, including patients with constipation (276 cases) , recurrent Clostridium Difficile infection (RCDI, 61 cases) , ulcerative colitis (44 cases) , irritable bowel syndrome (15 cases) and Crohn's disease (10 cases). Donors were completely unrelated, 18-to 50-year-old non-pregnant healthy adult, with healthy lifestyle and habits, without taking antibiotics, probiotics and other probiotics history within 3 months. There were three routes of FMT administration: patients received 6 days of frozen FMT by nasointestinal tube placed in the proximal jejunum under gastroscope (319 cases) ; patients received capsules FMT per day for 6 consecutive days (46 cases) or once 600 ml of treated fecal liquid infusion into colon and terminal ileum by colonoscopy (41 cases).
ResultsClinical cure rate and improvement rate of different diseases receiving FMT were respectively as follows: RCDI was 85.2% (52/61) and 95.1% (58/61) ; constipation was 40.2% (111/276) and 67.4% (186/276) ; ulcerative colitis was 34.1% (15/44) and 68.2% (30/44) ; irritable bowel syndrome was 46.7% (7/15) and 73.3% (11/15) and Crohn disease was 30.0% (3/10) and 60.0% (6/10). RCDI had the best efficacy among these diseases (P < 0.01). There was no significant difference between the three routes of FMT administration ( P = 0.829). The clinical cure rate and improvement rate of different routes were 43.3% (138/319) and 58.6% (187/319) respectively in nasogastric transplantation group, 41.5% (17/41) and 61.0% (25/41) in colonoscopy group, 37.0% (17/46) and 63.0% (29/46) in the capsule transplantation group. There was no serious adverse event during the follow-up. The most common side effects were respiratory discomfort (27.3%, 87/319) and increased venting (51.7% , 165/319) in nasogastric transplantation group. Diarrhea was the most common complication in colonoscopy group (36.6%, 15/41). The main symptoms were increased venting (50.0% , 23/46) and nausea (34.8% , 16/46) in oral capsule group. Side effect symptoms disappeared after the withdraw of nasogastric tube, or at the end of treatment, or during hospitalization for 1-3 days.
ConclusionsFMT is effective for many gastrointestinal disorders. No significant adverse event is found, while the associated mechanism should be further explored.
Key words:
Fecal microbiota transplantation; Gastrointestinal disorders; Intestinal microenvironment treatment
Contributor Information
Li Ning
Intestinal Microenvironment Treatment Center, Department of General Surgery, Nanjing General Hospital, Nanjing 210002, China
Tian Hongliang
Ma Chunlian
Ding Chao
Ge Xiaolong
Gu Lili
Zhang Xuelei
Yang Bo
Hua Yue
Zhu Yifan
Zhou Yan
